International and russian experience in treating children’s flu

Abstract

The article presents an extensive clinical experience about the treatment and prevention of influenza by oseltamivir for children and adults including high-risk group patients through different countries around the world over the past 17 years. The article reveals the causes of resistance to oseltamivir with a relative evolution proportion. The new domestic drug Nomides (oseltamivir), which manufactured by Pharmasintez JSC (Russia) in accordance with the Good Manufacturing Practice (GMP), has been represented in the article by unique dosage forms 30 and 45 mg on the Russian market for childrens older than one years old.

Keywords

• flu
• morbidity
• children
• oseltamivir
• nomides